| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 32% | Stephens & Co. | → $275 | Reiterates | Overweight → Overweight |
| 10/11/2023 | 51.2% | Stephens & Co. | → $315 | Reiterates | Overweight → Overweight |
| 08/07/2023 | 22.4% | Truist Securities | $264 → $255 | Maintains | Hold |
| 08/07/2023 | 22.4% | Raymond James | $272 → $255 | Maintains | Outperform |
| 08/04/2023 | 51.2% | JMP Securities | $330 → $315 | Maintains | Outperform |
| 07/27/2023 | 51.2% | Stephens & Co. | $305 → $315 | Maintains | Overweight |
| 07/19/2023 | 25.28% | Morgan Stanley | $261 → $261 | Reiterates | Equal-Weight → Equal-Weight |
| 06/21/2023 | — | Needham | Downgrades | Buy → Hold | |
| 06/12/2023 | 36.8% | RBC Capital | → $285 | Reiterates | → Outperform |
| 05/30/2023 | 40.64% | CL King | → $293 | Initiates Coverage On | → Buy |
| 05/30/2023 | 25.28% | Morgan Stanley | → $261 | Assumes | → Equal-Weight |
| 05/09/2023 | 58.4% | JMP Securities | → $330 | Reiterates | → Market Outperform |
| 05/08/2023 | 30.56% | Raymond James | $259 → $272 | Maintains | Outperform |
| 04/26/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 04/18/2023 | 20% | Mizuho | $220 → $250 | Maintains | Neutral |
| 04/17/2023 | 26.72% | Truist Securities | $250 → $264 | Maintains | Hold |
| 03/30/2023 | 58.4% | JMP Securities | → $330 | Reiterates | → Market Outperform |
| 02/27/2023 | 20% | Truist Securities | $260 → $250 | Maintains | Hold |
| 02/24/2023 | 24.32% | Raymond James | $231 → $259 | Maintains | Outperform |
| 02/24/2023 | 39.68% | Needham | → $291 | Reiterates | → Buy |
| 01/31/2023 | 24.8% | Truist Securities | $272 → $260 | Maintains | Hold |
| 01/06/2023 | 34.4% | Morgan Stanley | $236 → $280 | Maintains | Equal-Weight |
| 12/28/2022 | 41.6% | Stephens & Co. | $280 → $295 | Maintains | Overweight |
| 12/20/2022 | 30.56% | Truist Securities | $225 → $272 | Maintains | Hold |
| 10/28/2022 | 47.84% | RBC Capital | $342 → $308 | Maintains | Outperform |
| 10/28/2022 | 34.4% | Stephens & Co. | $305 → $280 | Maintains | Overweight |
| 10/28/2022 | 8% | Truist Securities | $220 → $225 | Maintains | Hold |
| 10/28/2022 | 10.88% | Raymond James | $266 → $231 | Maintains | Outperform |
| 10/28/2022 | 9.92% | Wells Fargo | $248 → $229 | Maintains | Equal-Weight |
| 10/28/2022 | 58.4% | JMP Securities | $370 → $330 | Maintains | Market Outperform |
| 10/26/2022 | 5.6% | Mizuho | → $220 | Initiates Coverage On | → Neutral |
| 10/14/2022 | 46.4% | Stephens & Co. | → $305 | Reinstates | → Overweight |
| 10/12/2022 | 0.8% | Jefferies | → $210 | Initiates Coverage On | → Hold |
| 10/11/2022 | 13.28% | Morgan Stanley | $278 → $236 | Maintains | Equal-Weight |
| 09/22/2022 | 15.68% | Truist Securities | $265 → $241 | Maintains | Hold |
| 08/01/2022 | 27.68% | Raymond James | $325 → $266 | Maintains | Outperform |
| 07/29/2022 | 33.44% | Morgan Stanley | $300 → $278 | Maintains | Equal-Weight |
| 07/29/2022 | 77.6% | JMP Securities | $430 → $370 | Maintains | Market Outperform |
| 07/29/2022 | 19.04% | Wells Fargo | → $248 | Downgrades | Overweight → Equal-Weight |
| 07/15/2022 | 44% | Morgan Stanley | $343 → $300 | Maintains | Equal-Weight |
| 07/06/2022 | — | Wolfe Research | Initiates Coverage On | → Outperform | |
| 05/23/2022 | 52.16% | Truist Securities | $340 → $317 | Maintains | Hold |
| 05/23/2022 | 56% | Raymond James | $355 → $325 | Maintains | Outperform |
| 05/23/2022 | 82.4% | RBC Capital | $390 → $380 | Maintains | Outperform |
| 05/09/2022 | 51.2% | B of A Securities | → $315 | Initiates Coverage On | → Neutral |
| 04/29/2022 | 64.64% | Morgan Stanley | $378 → $343 | Maintains | Equal-Weight |
| 04/29/2022 | 70.4% | Raymond James | $380 → $355 | Maintains | Outperform |
| 04/29/2022 | 87.2% | RBC Capital | $415 → $390 | Maintains | Outperform |
| 04/29/2022 | 70.4% | Needham | $400 → $355 | Maintains | Buy |
| 04/13/2022 | 77.6% | Truist Securities | → $370 | Initiates Coverage On | → Hold |
| 02/25/2022 | 81.44% | Morgan Stanley | $383 → $378 | Maintains | Equal-Weight |
| 02/25/2022 | 82.4% | Raymond James | $370 → $380 | Maintains | Outperform |
| 02/23/2022 | 77.6% | Raymond James | $391 → $370 | Maintains | Outperform |
| 01/31/2022 | 92% | Needham | $425 → $400 | Maintains | Buy |
| 01/07/2022 | 83.84% | Morgan Stanley | $431 → $383 | Downgrades | Overweight → Equal-Weight |
| 01/04/2022 | 56% | Piper Sandler | $465 → $325 | Downgrades | Overweight → Neutral |
| 12/13/2021 | 70.4% | Wells Fargo | $450 → $355 | Maintains | Overweight |
| 12/10/2021 | 99.2% | RBC Capital | → $415 | Initiates Coverage On | → Outperform |
| 10/29/2021 | 87.68% | Raymond James | $440 → $391 | Maintains | Outperform |
| 10/29/2021 | 106.88% | Morgan Stanley | $478 → $431 | Maintains | Overweight |
| 10/29/2021 | 106.4% | JMP Securities | $470 → $430 | Maintains | Market Outperform |
| 10/07/2021 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 08/02/2021 | 110.72% | Keybanc | $448 → $439 | Maintains | Overweight |
| 07/30/2021 | 99.2% | SVB Leerink | $410 → $415 | Maintains | Market Perform |
| 07/19/2021 | 96.8% | SVB Leerink | $485 → $410 | Downgrades | Outperform → Market Perform |
| 04/30/2021 | 132.8% | SVB Leerink | $475 → $485 | Maintains | Outperform |
| 04/30/2021 | 129.44% | Morgan Stanley | $450 → $478 | Maintains | Overweight |
| 03/12/2021 | 130.4% | Raymond James | $460 → $480 | Maintains | Strong Buy |
| 02/26/2021 | 120.8% | Raymond James | $440 → $460 | Maintains | Strong Buy |
| 01/27/2021 | 111.2% | JMP Securities | $375 → $440 | Maintains | Market Outperform |
| 01/08/2021 | 111.68% | KeyBanc | $382 → $441 | Maintains | Overweight |
| 01/06/2021 | 113.6% | Needham | $406 → $445 | Maintains | Buy |
| 12/15/2020 | 116% | Morgan Stanley | $375 → $450 | Maintains | Overweight |
| 12/15/2020 | 116% | SVB Leerink | $415 → $450 | Maintains | Outperform |
| 12/03/2020 | 111.2% | Raymond James | $400 → $440 | Maintains | Strong Buy |
| 11/02/2020 | 83.36% | Keybanc | → $382 | Upgrades | Sector Weight → Overweight |
| 10/30/2020 | 80% | Morgan Stanley | $400 → $375 | Maintains | Overweight |
| 10/30/2020 | 92% | Raymond James | $440 → $400 | Maintains | Strong Buy |
| 10/30/2020 | 99.2% | SVB Leerink | $430 → $415 | Maintains | Outperform |
| 07/31/2020 | 111.2% | Raymond James | $400 → $440 | Maintains | Strong Buy |
| 07/31/2020 | 92% | Morgan Stanley | $380 → $400 | Maintains | Overweight |
| 05/01/2020 | 96.8% | UBS | $440 → $410 | Maintains | Buy |
| 05/01/2020 | 84.8% | JMP Securities | $395 → $385 | Maintains | Market Outperform |
| 05/01/2020 | 80% | Wells Fargo | $365 → $375 | Maintains | Overweight |
| 05/01/2020 | 82.4% | Morgan Stanley | $350 → $380 | Maintains | Overweight |
| 05/01/2020 | 92% | Raymond James | $360 → $400 | Maintains | Strong Buy |
| 04/03/2020 | 72.8% | Raymond James | $450 → $360 | Maintains | Strong Buy |
| 03/27/2020 | 68% | Morgan Stanley | $405 → $350 | Maintains | Overweight |
| 03/23/2020 | 32% | Stephens & Co. | $425 → $275 | Maintains | Overweight |
| 02/24/2020 | 81.44% | Barclays | $365 → $378 | Maintains | Equal-Weight |
| 02/21/2020 | 111.2% | UBS | $430 → $440 | Maintains | Buy |
| 02/21/2020 | 116% | Raymond James | $415 → $450 | Maintains | Strong Buy |
| 02/21/2020 | 104% | Stephens & Co. | $400 → $425 | Maintains | Overweight |
| 01/31/2020 | 103.04% | Needham | $408 → $423 | Maintains | Buy |
| 01/17/2020 | 104% | Wells Fargo | $415 → $425 | Maintains | Overweight |
| 12/18/2019 | 106.4% | UBS | $415 → $430 | Maintains | Buy |
| 12/17/2019 | 94.4% | Morgan Stanley | $392 → $405 | Maintains | Overweight |
| 11/04/2019 | 75.2% | Barclays | $356 → $365 | Maintains | Equal-Weight |
| 10/07/2019 | 99.2% | Raymond James | $420 → $415 | Maintains | Strong Buy |
| 09/04/2019 | 94.4% | SVB Leerink | $395 → $405 | Maintains | Outperform |
| 08/05/2019 | 70.88% | Barclays | $309 → $356 | Maintains | Equal-Weight |
| 08/05/2019 | 89.6% | JMP Securities | $325 → $395 | Maintains | Market Outperform |
| 08/02/2019 | 101.6% | Raymond James | $350 → $420 | Maintains | Strong Buy |
| 08/02/2019 | 88.16% | Morgan Stanley | $345 → $392 | Maintains | Overweight |
| 07/16/2019 | 65.6% | Morgan Stanley | $320 → $345 | Maintains | Overweight |
| 06/11/2019 | 65.6% | Wells Fargo | → $345 | Initiates Coverage On | → Outperform |
| 04/24/2019 | 56% | Needham | → $325 | Downgrades | Strong Buy → Buy |
| 04/15/2019 | 48.32% | Barclays | $287 → $309 | Maintains | Equal-Weight |
| 03/27/2019 | 67.04% | Raymond James | $320 → $348 | Maintains | Strong Buy |
| 02/26/2019 | 51.2% | Morgan Stanley | $305 → $315 | Maintains | Overweight |
| 01/02/2019 | 46.4% | Morgan Stanley | $295 → $305 | Maintains | Overweight |
| 11/28/2018 | 48.8% | UBS | → $310 | Initiates Coverage On | → Buy |
What is the target price for Teleflex (TFX)?
The latest price target for Teleflex (NYSE: TFX) was reported by Stephens & Co. on November 3, 2023. The analyst firm set a price target for $275.00 expecting TFX to rise to within 12 months (a possible 32.00% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Teleflex (TFX)?
The latest analyst rating for Teleflex (NYSE: TFX) was provided by Stephens & Co., and Teleflex reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Teleflex (TFX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teleflex, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teleflex was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Teleflex (TFX) correct?
While ratings are subjective and will change, the latest Teleflex (TFX) rating was a reiterated with a price target of $0.00 to $275.00. The current price Teleflex (TFX) is trading at is $208.33, which is within the analyst's predicted range.